首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >HDL-C vs HDL-P: How Changing One Letter Could Make a Difference in Understanding the Role of High-Density Lipoprotein in Disease
【24h】

HDL-C vs HDL-P: How Changing One Letter Could Make a Difference in Understanding the Role of High-Density Lipoprotein in Disease

机译:HDL-C与HDL-P:更改一个字母如何在理解高密度脂蛋白在疾病中的作用上有所作为

获取原文
           

摘要

Before about 2006, most papers focusing on high-density lipoprotein (HDL)2 contained an introductory sentence that touted its protective role against cardiovascular disease (CVD), usually via the reverse transport of cholesterol away from the vessel wall. This was based on a mountain of epidemiological evidence showing an inverse correlation between plasma concentrations of HDL cholesterol (HDL-C) and CVD as well as thousands of in vitro and animal model studies demonstrating the cholesterol-carrying capacity of the particles. More recently, however, confidence in a direct atheroprotective role for HDL has wavered. HDL-targeted drugs such as niacin and 2 different cholesteryl ester transfer protein (CETP) inhibitors have failed in clinical trials, despite raising HDL-C (nicely reviewed in (1)). Furthermore, recent Mendelian randomization analyses suggest that genetic anomalies that raise HDL-C fail to impart the CVD protections predicted by epidemiologic findings (2). This has prompted some to regard HDL as a marker or byproduct of other, more directly atheroprotective, mechanisms. On the other hand, large studies have shown that the cholesterol efflux capacity of primarily HDL-containing [i.e., low-density lipoprotein (LDL)-depleted] serum is a robust predictor of CVD, even better than HDL-C (3), suggesting that HDL's mobilization of cellular cholesterol may indeed be atheroprotective.So why has it been so difficult to determine whether HDL plays a direct protective role in CVD? Some argue that the picture has been clouded by the way HDL has been traditionally quantified. The HDL-C measurement targets only a single HDL component, and a relatively minor one at that: a maximum of 20% of HDL mass is cholesterol or its ester. Ideally, one would like to know the actual number of HDL particles (HDL-P) circulating in plasma, not simply how much cholesterol they are carrying. This is a relatively easy determination for LDL. Because each particle contains a single copy …
机译:在2006年左右之前,大多数专注于高密度脂蛋白(HDL)2的论文都在介绍性句子中大肆宣传了其对心血管疾病(CVD)的保护作用,通常是通过胆固醇从血管壁的反向转运来实现的。这是基于大量的流行病学证据,显示高密度脂蛋白胆固醇(HDL-C)和CVD的血浆浓度之间呈负相关,以及成千上万的体外和动物模型研究证明了颗粒的胆固醇携带能力。然而,最近,人们对HDL具有直接的抗动脉粥样硬化作用的信心动摇了。尽管提高了HDL-C水平,但针对HDL的药物(例如烟酸和2种不同的胆固醇酯转移蛋白(CETP)抑制剂)在临床试验中失败了(在(1)中进行了详尽的评论)。此外,最近的孟德尔随机分析表明,升高HDL-C的遗传异常无法赋予流行病学发现所预测的CVD保护(2)。这促使一些人将HDL视为其他更直接的抗动脉粥样硬化机制的标志或副产物。另一方面,大量研究表明,主要含有HDL的[即低密度脂蛋白(LDL)耗尽的]血清的胆固醇外流能力是CVD的可靠预测指标,甚至优于HDL-C(3),提示HDL调动细胞胆固醇确实具有抗动脉粥样硬化作用,那么为什么很难确定HDL是否在CVD中起直接保护作用呢?有人认为,图片被传统上量化HDL的方式蒙上了一层阴影。 HDL-C测量仅针对单个HDL成分,而在这一点上相对较小:HDL质量的最大20%是胆固醇或其酯。理想情况下,人们想知道血浆中循环的HDL颗粒(HDL-P)的实际数量,而不只是知道它们携带多少胆固醇。对于LDL,这是相对容易的确定。因为每个粒子都包含一个副本...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号